| Risk in biologic-naïve RA patients | Risk in TNFi-exposed patients | TNFi-exposed vs biologic-naïve patients | ||||
---|---|---|---|---|---|---|---|
Observed | Expected | SIR* (95% CI) | Observed | Expected | SIR (95% CI) | RR (95% CI) | |
All invasive cancers | 49 | 32.27 | 1.52 (1.16, 2.02) | 107 | 102.62 | 1.04 (0.87, 1.27) | 0.71 (0.46, 1.08) |
Melanoma | 4 | 2.65 | 1.51 (0.57, 5.35) | 12 | 9.17 | 1.31 (0.76, 2.46) | 1.18 (0.29, 4.70) |
Lung | 9 | 3.35 | 2.69 (1.43, 5.68) | 16 | 9.45 | 1.69 (1.05, 2.90) | 0.38 (0.12, 1.20) |
Lymphoid cancers | 5 | 2.71 | 1.84 (0.78, 5.47) | 15 | 8.24 | 1.82 (1.12, 3.18) | 0.79 (0.25, 2.55 |
Bowel | 7 | 4.59 | 1.53 (0.74, 3.66) | 10 | 13.11 | 0.76 (0.42, 1.54) | 0.75 (0.17, 3.29) |
Prostate | 10 | 4.75 | 2.10 (1.18, 4.12) | 12 | 13.67 | 0.88 (0.51, 1.64) | 0.67 (0.23, 1.99) |
Breast | 8 | 4.58 | 1.75 (0.90, 3.86) | 17 | 19.35 | 0.88 (0.56, 1.47) | 0.50 (0.22, 1.16) |